These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38500351)

  • 1. New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs.
    Pinto SFT; Santos HA; Sarmento BFCC
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1952. PubMed ID: 38500351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel strategies in the oral delivery of antidiabetic peptide drugs - Insulin, GLP 1 and its analogs.
    Ismail R; Csóka I
    Eur J Pharm Biopharm; 2017 Jun; 115():257-267. PubMed ID: 28336368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency.
    Alavi SE; Cabot PJ; Moyle PM
    Mol Pharm; 2019 Jun; 16(6):2278-2295. PubMed ID: 31050435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
    Holz GG; Chepurny OG
    Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the treatment of diabetes mellitus with glucagon-like peptide-1.
    Holst JJ; Deacon C; Toft-Nielsen MB; Bjerre-Knudsen L
    Ann N Y Acad Sci; 1998 Dec; 865():336-43. PubMed ID: 9928027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy.
    Araújo F; Shrestha N; Gomes MJ; Herranz-Blanco B; Liu D; Hirvonen JJ; Granja PL; Santos HA; Sarmento B
    Nanoscale; 2016 May; 8(20):10706-13. PubMed ID: 27150301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus.
    Vilsbøll T; Knop FK
    BioDrugs; 2008; 22(4):251-7. PubMed ID: 18611067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel strategy for oral peptide delivery in incretin-based diabetes treatment.
    Xu Y; Van Hul M; Suriano F; Préat V; Cani PD; Beloqui A
    Gut; 2020 May; 69(5):911-919. PubMed ID: 31401561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
    Vilsbøll T; Holst JJ; Knop FK
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):453-62. PubMed ID: 19748063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.